Acceleron Pharma Inc. (XLRN) and Celgene Corp. (CELG) announced preliminary results from an ongoing investigator initiated Phase 2 study with investigational drug sotatercept in patients with myelofibrosis at the 58th Annual Meeting of the American Society of Hematology or ASH in San Diego, California.
from RTT - Biotech http://ift.tt/2gY3tNA
via IFTTT
No comments:
Post a Comment